Procept Biorobotics Demonstrates Waterjet Treatment for BPH

Summary

Procept Biorobotics Corporation presented its Aquablation therapy for benign prostatic hyperplasia (BPH) in August 2025, showcasing its innovative waterjet technology that balances safety and efficacy. The company highlighted its strong intellectual property and clinical evidence, with over 150 peer-reviewed publications. Positioned to capture a significant share of the $20 billion U.S. BPH surgical market, Procept has garnered support from key opinion leaders and is included in clinical guidelines. The full presentation is accessible via a provided link.Reuters

Impact Analysis

The introduction of Procept Biorobotics’ Aquablation therapy represents a significant product/service milestone, potentially expanding the company’s footprint in the U.S. BPH surgical market, estimated at $20 billion. First-order effects include enhanced growth prospects due to the innovative technology’s safety and efficacy, backed by substantial clinical evidence and intellectual property. Support from key opinion leaders and inclusion in clinical guidelines further bolster its market position. Risks might involve the speed of clinical adoption and responses from competitors with alternative therapies. Second-order effects could influence peer companies in the medical device sector, prompting them to accelerate innovation or adjust market strategies. For investors, opportunities may lie in the potential increase in Procept’s market share and revenue in the surgical market, with options strategies focusing on long-term growth prospects in the healthcare sector.Reuters